http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CA-2095141-A1

Outgoing Links

Predicate Object
assignee http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_42e94091a4fc81b8d0237117707cc7ee
classificationCPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-395
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-70
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-395
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-40
filingDate 1991-10-18-04:00^^<http://www.w3.org/2001/XMLSchema#date>
inventor http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d0dce11e113bb93b510cf741631684e5
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_922d648cf2783ac52302d9689b5529f7
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b65bdd729ff0b5276c4ea52804511c54
publicationDate 1992-05-06-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber CA-2095141-A1
titleOfInvention Synergistic therapy with combinations of anti-tumor antibodies and biologically active agents
abstract Methods of inhibiting tumor growth and development are described in which a combination of anti-tumor antibodies and biologically active agents, such as chemotherapeutic drugs, are utilized. The combination of anti-tumor antibody, such as the BR96 antibody, with a chemotherapeutic drug, such as doxorubicin or mitomycin C, is shown to produce a synergistic effect to inhibit tumor development and tumor cell growth.
priorityDate 1990-11-05-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID5746
http://rdf.ncbi.nlm.nih.gov/pubchem/taxonomy/TAXID8060
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419553757
http://rdf.ncbi.nlm.nih.gov/pubchem/protein/ACCP81497
http://rdf.ncbi.nlm.nih.gov/pubchem/protein/ACCQ9GMY8
http://rdf.ncbi.nlm.nih.gov/pubchem/anatomy/ANATOMYID8060
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID31703
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419564680
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419535365
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID22094277
http://rdf.ncbi.nlm.nih.gov/pubchem/protein/ACCP00792
http://rdf.ncbi.nlm.nih.gov/pubchem/protein/ACCQ9GMY6
http://rdf.ncbi.nlm.nih.gov/pubchem/protein/ACCP13636
http://rdf.ncbi.nlm.nih.gov/pubchem/protein/ACCP00793
http://rdf.ncbi.nlm.nih.gov/pubchem/protein/ACCQ9GMY7
http://rdf.ncbi.nlm.nih.gov/pubchem/protein/ACCP11489
http://rdf.ncbi.nlm.nih.gov/pubchem/protein/ACCP27821
http://rdf.ncbi.nlm.nih.gov/pubchem/protein/ACCP00791
http://rdf.ncbi.nlm.nih.gov/pubchem/protein/ACCP27822
http://rdf.ncbi.nlm.nih.gov/pubchem/protein/ACCQ9N2D4
http://rdf.ncbi.nlm.nih.gov/pubchem/protein/ACCP28712
http://rdf.ncbi.nlm.nih.gov/pubchem/protein/ACCP28713

Total number of triples: 39.